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ABSTRACT 
Background: According to the 2010 edition of the UNAIDS Report on the global AIDS epidemic, an 
estimated 320 000 (20%) fewer people died of AIDS-related causes in South Africa in 2009 than in 
2004 due to the increase in availability of anti-retroviral medicines.(2)  With this positive trend, the 
mindset should be shifted towards reducing adverse effects of ART. The need for permanent ART 
treatment and the significant increase in life expectancy have led to the observation of new, frequent, 
and sometimes severe drug-related adverse effects.(4)  One of the most challenging and potentially 
dangerous side-effects is hyperlactataemia (Hlac) that may evolve to lactic acidosis (LA)(5)  ART–
associated Hlac may be asymptomatic, or symptomatic which in the extreme case can progress to life 
threatening acidosis. The latter, i.e. lactic acidosis is a fairly frequent and often misdiagnosed or under 
diagnosed and potentially fatal side effect of ARTs. (6) 
Objectives: To explore the relationship between Hlac/LA and gender, weight, dosage CD4 and 
regimen alterations in HIV patients on ARTs and to compare the earlier regimens to the revised 
regimens as independent risk factors for Hlac and LA. Sample size would be based on the hypothesis 
that newer regimens would reduce the incidence of Hlac and LA. 
Methods: A Retrospective study was conducted by reviewing 3 741 patient files from August 2004 
to December 2007. This study was to assess the incidence and risk factors of Hlac/LA. Hlac was 
defined as a venous lactate measurement of ≥2.3mmol/L and LA was ≥5mmol/L. Immunological, 
virological, haemotological and biochemical results were recorded for all the patients. A second phase 
involved a Prospective study. Patients who were on treatment for >12 months were randomly 
selected from the queue at the clinic between the September 2008 and December 2009. 
Immunological, virological, haematological and biochemical information was recorded for all patients 
selected. Analysis involved descriptive statistics, comparison of means, frequency analysis and 
multivariate analysis. 
Results: Two-hundred and thirty two patients were identified with elevated lactate levels in the 
retrospective study. The incidence was 6.2% in this population, with gastro-intestinal symptoms, 
peripheral neuropathy, abdominal tenderness, rash and upper respiratory tract infection being the 
significant symptoms. The major risk factor was a low CD4 count. The prospective study included 292 
patients with 24.3% with Hlac/LA with peripheral neuropathy (p 0.209), gastrointestinal symptoms 
(nausea, vomiting) (p 0.148) and abdominal tenderness (p 0.214) were the most significant symptoms. 
In terms of the hypothesis that newer regimens would lower the incidence of elevated lactate levels by 
50%, the observed incidence of 24.3% is no different from previously reported rates. This therefore 
shows that although regimen changes have been implemented the overall incidence of Hlac appears 
to be unchanged but the LA rate was found to be significantly lower than before, 6.8 cases per 1000 
patient years vs ±19 cases per 1000 person years.(16) Gastro-intestinal symptoms but not peripheral 
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neuropathy; with low CD4 count, weight loss and low weight on entry were the significant risk factors, 
which is most likely representative of advanced disease.  Conclusions: Although newer regimens 
have been introduced, Hlac/LA still exist. Healthworkers need to be on high alert for Hlac/LA 
particularly if a patient enters into the ART program with a low CD4 count and a low weight.  
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CHAPTER 1 
1.INTRODUCTION AND BACKGROUND 
 
1.1INTRODUCTION 
South Africa has the sixth highest prevalence of Human Immunodeficiency Virus (HIV) infection 
in the world, with 10.6% of the population estimated to be infected. The total number of people 
living with HIV is estimated to be 5.21million. Approximately one-fifth of South African women in 
the reproductive age are HIV positive.(1)  According to the 2010 edition of the UNAIDS Report 
on the global AIDS epidemic, an estimated 320 000 (20%) fewer people died of AIDS-related 
causes in South Africa in 2009 than in 2004 due to the increase in availability of anti-retroviral 
medicines.(2)  With this positive trend of improved drug treatment and fewer AIDS-related 
deaths, the mindset should be shifted towards reducing adverse effects of anti-retroviral agents 
and improving the quality of life of HIV-infected people. Anti-retroviral therapies (ARTs) have 
introduced the possibility of sustained suppression of HIV replication, recovery of the immune 
system and a substantial decrease in the frequency of opportunistic infections.(3)  However, the 
need for permanent anti-retroviral treatment and the significant increase in life expectancy have 
led to the observation of new, frequent, and sometimes severe drug-related adverse effects.(4)  
One of the most challenging and dangerous side-effects is hyperlactataemia (Hlac) that may 
evolve to lactic acidosis (LA), particularly with the Nucleoside Reverse Transcriptase Inhibitors 
(NRTI).(5)  ART–associated Hlac may be asymptomatic, or symptomatic which in the extreme 
case can progress to life threatening acidosis. The latter, i.e. LA is a fairly frequent and often 
misdiagnosed or under-diagnosed and potentially fatal side effect of ARTs. (6)  
 
Table 1.1:Categories and Examples of Anti-Retroviral Drugs (7) 
Nucleoside Reverse 
Transcriptase Inhibitors 
(NRTI) and analogue 
mimicked 
Non-nucleoside 
Reverse Transcriptase 
Inhibitors (NNRTI) 
Protease Inhibitors 
(PI) 
Stavudine (d4T) Thymidine Efavirenz 
Indinavir 
 
Zidovudine (AZT) Thymidine Nevirapine Ritonavir 
Lamivudine (3TC) Non-
Thymidine 
 Lopinavir  
Abacavir (ABC) Non-Thymidine   
Didanosine (DDI) Non-
Thymidine 
  
Tenofovir Non-Thymidine   
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*Thymidine analogues (structurally related to thymidine, a DNA building block) 
**Non-thymidine analogues (structurally related to other building blocks such as adenosine, cytosine, 
and guanosine). 
 
Figure 1.1:Entry of HIV into Cell and Mechanism of Replication (8) 
 
As shown in Figure 1.1 the reverse transcriptase enzyme is essential for completion of the early 
stages of HIV replication, and the protease enzyme is required for the assembly and maturation 
of fully infectious viral progeny.(9)  Nucleoside analogues bear a structural resemblance to the 
natural building blocks of DNA: the nucleosides adenosine and guanosine, thymidine and 
cytidine. Nucleoside analogues are triphosphorylated within the cell, and some undergo further 
modifications (didanosine, for example, is converted into its active moiety, 2',3'-
dideoxyadenosine-5'-triphosphate). Nucleotide analogues resemble monophosphorylated 
nucleosides, and therefore require only two additional phosphorylations to become active 
inhibitors of DNA synthesis. Reverse transcriptase fails to distinguish the phosphorylated NRTIs 
from their natural counterparts, and the enzyme attempts to use the drugs in the synthesis of 
viral DNA. When an NRTI is incorporated into a strand of DNA being synthesized, the addition 
of further nucleotides is prevented and a full-length copy of the viral DNA is not produced. 
NNRTIs also inhibit the synthesis of viral DNA, but rather than act as false analogues, the 
NNRTIs bind to reverse transcriptase and inhibit the enzymes activity. Protease inhibitors bind 
to the active site of the viral protease enzyme, preventing the processing of viral proteins into 
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functional conformations. Viral particles are still produced when the protease is inhibited, but 
these particles are not effective at infecting new cells.(10)  
Modern convention is to use Highly Active Anti-retroviral Therapy (HAART) which usually 
contains two NRTIs combined with a Protease Inhibitor (PI) or a Non-Nucleoside Transciptase 
Inhibitor (NNRTI).(11)  The South African national HIV treatment guidelines recommend stavudine 
(d4T), lamivudine (3TC), and efavirenz (EFV;regimen 1a) or nevirapine (NVP;regimen 1b) as an 
initial regimen, and didanosine (DDI), zidovudine (AZT) and lopinavir/ritonavir (LPV/R) as the 
subsequent treatment regimen (regimen 2). Agents included in regimen 2 are available for 
substitution following adverse events to agents in regimen 1, or for treatment failure following 
regimen 1 exposure. (12)  Combination ART has been the standard of care for more than a 
decade, but ART combinations are not randomly allocated; rather they follow biological rationale 
and clinical experience, making it difficult over different time periods to assess any long term 
adverse effects of an individual drug, or changes in vivo intracellular processes such as lactate 
metabolism and mitochondrial function.  More recent recommendations favour regimens based 
on abacavir or tenofovir over ones containing the thymidine analogues, on the basis of a lower 
risk of adverse events. However, the cost and availability of such alternatives make this difficult 
to implement on a large scale. In the context of expanding access to anti-retroviral therapy, 
particularly in resource-limited countries, NRTIs and particularly thymidine analogues (i.e. 
zidovudine and stavudine) are the cornerstone of first-line ART regimens.(13) 
 
Almost all studies to date suggest that dideoxynucleosides, in particular stavudine, are 
associated with the development of Hlac and severe LA.(13,14-16) In 2005, Calza et al reported 
that most cases of LA during anti-retroviral treatment were associated with stavudine and 
didanosine therapy. This observation is in agreement with the relative affinities of various 
nucleoside analogues for mitochondrial DNA polymerase, and their relative potencies with 
regard to the inhibitory effects on mitochondrial DNA (mtDNa) replication in vitro.  
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Figure 1.2:Mitochondrial Drug Toxicity (17)  
 
The relative potency of these agents in reducing mtDNA content has repeatedly been found to 
be: zalcitabine>didanosine>stavudine>lamivudine>zidovudine>abacavir. Abacavir and tenofovir 
have been found to have a very low affinity for mitochondrial DNA polymerase, and a very low 
potency in inhibiting the mtDNA production (Figure 1.2).  Non-nucleoside reverse-transcriptase 
inhibitors show a very low affinity for mitochondrial DNA polymerase, so it has been suggested 
that combinations of NNRTIs and PIs could be a safe treatment regimen for patients with 
previous Hlac.(18) 
 
In a host of studies over the past decade a few risk factors and associations have been clearly 
established. Hyperlactataemia/Lactic acidosis have been shown to be associated with female 
gender, advanced immunosuppression, excellent compliance, duration of treatment of more 
than 6 months, chronic muscle or kidney disease, chronic hepatitis B or C infection, low CD4 
count before starting a regimen containing NRTI, and possibly with ethnicity.(3,13,15,16)  Patients 
≥75kg at ART initiation with weight gain of ≥6kg in the first 3 months on therapy, and with 
peripheriphal neuropathy, were most likely to present with symptomatic Hlac and LA. On the 
other hand, patients of low body weight and with high serum lactate levels are at a higher risk of 
dying. (19, 20)  Age can also be an independent predictor, with older patients being more likely to 
present with Hlac. Because NRTIs are known to be potential substrates of polymerase gamma, 
inhibition of this polymerase decreases mitochondrial DNA concentrations and thus the 
synthesis of mitochondrial enzyme protein subunits encoded by mitochondrial DNA. Alterations 
in mitochondrial function have been described during aging. This may explain why older 
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patients with physiologic alterations in their mitochondrial capacities are more likely to have 
higher lactate concentrations with NRTIs than younger patients.(21) 
Table 1.2:Most commonly Reported Risk Factors for Hyperlactataemia(3,13,16,22) 
 
 High Body Mass Index (BMI) 
 Female  
 Pregnancy 
 Underlying Liver Disease 
 Older Age 
 Combination of Stavudine or Didanosine or Stavudine alone. 
 Excellent Compliance 
 Duration of Treatment of more than 6 months 
 Chronic muscle or Kidney Disease 
 Low CD4 
 Advanced HIV-1-induced Immunosuppression 
 
1.2 PATHOPHYSIOLOGY 
Lactate, one of the components of the respiratory chain, is produced during the glycolytic 
pathway as a product of transformation of pyruvate. Intracellular processes are depicted in Fig 
1.3. When the oxygen supply of tissues is sufficient, the metabolism of pyruvate is primarily 
oxidative with no intracellular accumulation of lactate. However, impairment of oxygen supply or 
cytoplasmic accumulation of pyruvate may result in increased lactate formation.(23)  
 
 
Figure 1.3:Intracellular Energy Processes (18) 
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Under aerobic conditions, glycolysis feeds into the citric acid cycle and the electron transport 
chain where most of the free energy in glucose is harvested. If oxidative phosphorylation is 
interrupted because of respiratory chain enzyme depletion, ATP synthesis decreases and the 
NADH/NAD+ ratio rises, leading to the reduction of pyruvate by NADH to form lactate, which is 
the end-point of cytoplasmic glucose metabolism (Figure 1.3).  Normally, lactate concentration 
in venous blood reflects the equilibrium maintained between the rate of lactate production, and 
that of lactate utilization and elimination by liver and renal cortex. However, under various 
conditions of lactate excess, hepatic and renal clearance of lactic acid may be augmented, and 
other organs that are usually lactate producers, such as skeletal muscle, can become great 
lactate consumers. NRTI-related LA is almost always associated with impaired liver function 
manifested as massive hepatic steatosis or frank hepatic failure. Under these circumstances the 
liver has reduced lactate clearance capacity and also becomes a net lactate producer.(18) 
 
Given the similarities in function between HIV reverse transcriptase and human DNA 
polymerases it is not surprising that nucleoside analogues are competitive inhibitors of human 
DNA polymerases. The affinity of these agents appears to be greatest for mitochondrial DNA 
polymerase. Their use, therefore, could lead to depletion of mitochondrial DNA and hence 
diminish cellular respiratory function.(4,24)  In vitro, NRTIs have been shown to damage and 
deplete mtDNA, alter mitochondrial morphology and decrease cell viability. Cultured human 
cells exposed to varying concentrations of NRTIs have been shown to decrease mtDNA content 
quite rapidly, and significant changes in mtDNA have been followed by altered mitochondrial 
morphology and diminished cell growth (Figures 1.4; 1.5)  Coté et al have studied changes in 
mtDNA relative to nuclear DNA in peripheral blood cells of patients with symptomatic, NRTI-
induced Hlac. Increased serum lactate levels were associated with marked reductions in the 
ratios of mitochondrial to nuclear DNA which, during therapy, averaged 43% lower than those of 
HIV-infected, asymptomatic subjects not previously treated with anti-retroviral drugs. With drug 
use the decline in mtDNA preceded the increase in venous lactic acid levels, while on the other 
hand there was a statistically significant increase in the ratios of mitochondrial to nuclear DNA 
after the discontinuation of anti-retroviral treatment.(4) 
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Figure 1.4       Figure 1.5 
 
Figure 1.4: Normal Mitochondria in Response to ART 
Figure 1.5:Progressively Abnormal Mitochondria in Response to ART(5) 
 
Mitochondria treated with DDI and d4t showing swelling, reduced cristae and an increase in the 
number of cytoplasmic vacuole. (5) 
 
1.3CLASSIFICATION 
Hlac may be asymptomatic, or present with combinations of weight loss, nausea, vomiting and 
diarrhoea. Lactic acidosis is often difficult to diagnose because the presenting symptoms (e.g. 
nausea, emesis, abdominal pain, increased fatigue and unexpected weight loss) are non-
specific and may be the result of drugs, the underlying disease or an intercurrent problem 
(Fig.1.6).  On the other hand, pancreatitis, sepsis and certain pathological thermoregulatory 
states such as heat exhaustion can also cause serum lactate elevations.(25)  Severe LA is 
typically symptomatic, with rapid or precipitous progress to classical features of metabolic 
acidosis (ph <7.35 and arterial bicarbonate <22mEq/L(26)), accompanied by  hyperventilation, 
arrhythmias, and multiple organ failure.(19) Hlac in HIV is commonly categorized into one of 
three clinical and biochemical entities.(16) 
 
Asymptomatic Hlac (also referred to as subclinical Hlac): Here the lactate level is mildly to 
moderately raised (2.5-5mmol/L) and the patient is asymptomatic. Hlac may be transient or 
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prolonged, and has not been found to predict the onset of symptomatic or severe LA. Therefore 
routinely screening asymptomatic patients on NRTIs is not considered beneficial. (3) 
Symptomatic Hlac: In this category, patients again have mildly to moderately elevated lactate 
levels (2.5-5mmol/L), no acidosis, but are clinically symptomatic (Figure 1.6). This may be an 
early manifestation before the onset of acute, severe LA, and usually occurs in situations where 
tissues are well-perfused and buffering systems are able to prevent a fall in pH and 
development of metabolic acidosis. (3) 
Lactic acidosis: The criteria used to diagnose LA include serum lactate ≥5mmol/l, bicarbonate 
level <20mmol/l, arterial pH <7.34 and anion gap >12. Patients in this category are symptomatic 
and the mortality rate is high (Figure 1.6). A serum lactate concentration of >10mmol/l is 
considered to be an independent predictor of mortality, and a level 15mmol/l is associated with 
>60% mortality. (3) 
 
 
Figure 1.6:Clinical Manifestations of Hlac and LA, and Relationship to Arterial Blood  
pH Value(18) 
 
Variations in the frequency of the categories of Hlac seen across studies or groups of patients 
may be attributed to differences in the definition of Hlac and/or variations in potential risk factors 
for Hlac such as ART regimen, patient-related factors and co-morbidities. Furthermore, venous 
lactate measurement is vulnerable to spurious increases, and the techniques employed to 
minimize falsely elevated results may vary from study to study.(6)  
 
In 2008, Perez et al showed that in resource-poor settings it is difficult to definitively diagnose 
LA by laboratory measurement of lactate because of a lack of data related to the costs involved 
(equipment, transportation etc). In this regard, cost effective Point-Of-Care (POC) devices are 
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helpful in the measurement of lactate levels and have been validated.  The Accutrend lactate 
meter is an appropriate device for screening patients on HAART with or without symptoms of 
Hlac/LA. The use of this device decreases analytical and intervention time, and may help to 
prevent further morbidity and mortality in patients on an NRTI (stavudine)-based regimen.(9) 
Point-Of-Care devices eliminate the need to transport blood specimens on ice and provide a 
significant advantage in the measurement of lactic acid.(27) 
 
1.3PREVALENCE AND INCIDENCE 
Although symptomatic Hlac and metabolic acidosis are thought to be rare adverse effects, a 
recent study has shown that asymptomatic increased lactate concentration is a frequent event 
in patients receiving NRTIs, with an estimated prevalence range of 15% to 35%. Symptomatic 
Hlac and LA reportedly occur much less frequently, varying from 1.7 to 25.2 cases per 1000 
person-years of treatment with NRTIs. However, there is substantial variation in the calculated 
frequency due to the variety of case definitions employed.(18) 
 
A South African study in 2006 reported an incidence of 19 cases of LA (>5mmol/L) per 1 000 
person-years of treatment. All patients were on two NRTIs (d4T and 3TC), with 86% on 
efavirenz (EFV), and 14% on nevirapine as the third (non-NRTI) drug.(16)  In 2008,  Fabian et al, 
reported an incidence of symptomatic severe Hlac (>5mmol/L) of 20.5 cases per 1000 person-
years at Johannesburg Hospital, with 82.6% on stavudine, lamivudine and efavirenz, 10.4% on 
stavudine, lamivudine and nevirapine, 0.8% on zidovudine, didanosine and lopinavir/ritonavir, 
and 6.2% on various combinations.(15) In a similar study in Soweto, the overall incidence, where 
lactate of >4.5mmol/L was included, was 10.6 cases per 1000 patient-years of treatment. In this 
study, 66 of 67 patients were receiving stavudine and 5 patients were receiving didanosine.(14)  A 
study at Grey’s Hospital in western Kwa-zulu Natal in 2010, with all the patients being on 
stavudine, showed the overall incidence of LA (>5mmol/L) was 13.5 cases per 1000 patient 
years, and the overall incidence of Hlac (>2.2mmol/L) without acidosis was 31 cases per 1000 
patient years.(12) These results are summarized in Table 1.3. 
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Table 1.3:Summary of Research Articles (12, 13, 15, 16, 18, 20, 21, 28) 
Period 
Location of 
Study 
Incidence Rate Lactate Definition Symptoms Risk Factors Found 
1997-2004 London No 
information given 
Two consecutive 
lactates ≥5mmol/L 
No information given *exposure <12months 
*female gender 
d4T and didanosine exposure 
*age above 40years 
*advanced 
immunosuppression 
 
1999-2000 Western 
Australia 
None given Hlac 2.8-4.1mmol/L 
and LA  ≥5mmol/L  
No information given *d4T exposure 
*effect of d4T not confounded 
by longer NRTI history nor 
previous zidovudine exposure 
 
2000-2002 France None given Hlac 2.25-5mmol/L  
LA >5mmol/L. 
*weight loss from the 
initiation of the current 
regimen 
*gastrointestinal 
symptoms 
(vomiting,nausea, 
diarrhea) 
*respiratory symptoms 
(cough and dyspnea) 
*muscular symptoms 
(myalgia and cramps) 
 
*older age 
*drug regimens with 
stavudine or a combination of 
stavudine-didanosine 
*use of buprenorphine 
2004-2005 S. Africa 19 cases per 
1000 person-
years of 
treatment 
≥ 5mmol/L= 
LA 
*loss of appetite 
*abdominal pain 
*diarrhea 
*vomiting 
*shortness of breath 
 
* d4T exposure 
*female 
*overweight 
 
2004-2005 Italy 1.7 to 25.2 cases 
per 1000 person 
years 
Hlac ( 2-5mmol/L) 
LA (>5mmol/L) 
*asthenia, *malaise 
* nausea 
*vomiting 
* abdominal pain 
*weight loss, 
*tachypnoea, *dyspnoea 
* liver steatosis 
 
*concurrent therapy         on 
ddi and d4t 
2003-2005 South Africa None given Hlac ≥5mmol/L *weight loss of ≥2kg 
*rise in alanine 
aminotransferase 
* presence of one of 
three major symptoms 
(vomiting,nausea and 
abdominal pains) 
*peripheral neuropathy 
 
*female sex 
*baseline weight between 60 
and ≥75kg  at ART initiation 
and gaining ≥6kg in the first 3 
months 
 
2004-2005 South Africa 20.5 cases per 
1000 person-
years of ART 
LA /severe Hlac 
>5.0mmol/L 
*non-specific 
gastrointestinal 
symptoms 
*weight loss 
*symptomatic neuropathy 
 
*female 
 
2004-2006 South Africa 13.5 cases per 
1000 patient 
years. 
Hlac >2.2mmol/L and 
LA >5mmol/L 
*loss of weight 
*abdominal pain 
*loss of appetite 
*parasthesia 
*baseline CD4 count 
<10cells/mm
3
 at HAART 
initiation. 
 
 
 
11 
 
1.4BACKGROUND TO THE RESEARCH 
During a period of employment as the principal pharmacist at the Tshwane District Hospital from 
2005 to 2006, the constant recognition of patients presenting with and dying with/from elevated 
lactate at the Tshwane District Hospital sparked an interest in categorizing the risk factors for 
Hlac. The lack of knowledge within the team of health workers and the despondency of the 
patients generated the interest, enthusiasm and determination to complete the research. 
Although certain protocols were in place for recognition and possible prevention, Hlac was a 
common presentation. The practitioners changed stavudine from 40mg to 30mg, and replaced 
stavudine with zidovudine if a patient presented with symptomatic Hlac. Certain trends and 
associations were becoming noticeable, for example the use of stavudine in overweight women. 
Questions arose such as whether Hlac presented because of the anti-retrovirals, and/or what 
conditions could aggravate the condition.  Questions also arose as to whether weight, age and 
race affected Hlac.  Thus, this research aimed to explore the frequency of and risk factors for 
Hlac/LA with the later treatment protocols. This might not only assist the patients, but empower 
health workers to identify and then mitigate the risk factors for the condition, thereby providing a 
better quality of life for the already-compromised patients. 
 
1.5. AIM 
The Aim of the study was to determine the risk factors associated with lactic acidosis in adult 
HIV patients on ARVs in a public sector hospital in Gauteng. 
 
1.6 OBJECTIVES 
 To explore the relationship between Hlac/LA and gender, weight, CD4 status, dosage and 
regimen alterations in HIV patients on ARTs. 
 To compare the earlier regimens to the revised regimens as independent risk factors for 
Hlac and LA.  
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CHAPTER 2 
2.1METHODOLOGY 
2.1.1Study Design 
There were two components to the study:  
A Retrospective analysis of patient records from the Tshwane District Hospital, and a 
subsequent Prospective study of ART-naïve patients attending the same clinic. 
 
2.2.1.1Retrospective Review 
The retrospective study was to assess the incidence of and some risk factors for Hlac/LA in 
patients on ARTs. Data were obtained from hospital records of ART-treated HIV-positive 
patients who had been diagnosed with symptomatic Hlac or LA between August 2004 and 
December 2007.  Hlac was defined as a venous lactate measurement of ≥2.3mmol/L because 
the hospital protocol at the time classified 2.3mmol/L and greater as Hlac. Levels ≥5mmol/L 
were classified as LA.  
 
The inclusion criteria were as follows: 
1. Male or female patients’≥18 years of age   
2.  HIV positive and treated with anti-retrovirals for longer than 3 months. 
 
The collection protocol at the time is detailed below:  
 For lactate measurement the specimen was drawn from an un-cuffed arm. 
 It was then collected in a fluoride tube. 
 Thereafter, the tube was put on ice immediately and sent to the laboratory within 4 hours. 
 All the patients were well hydrated and did not exercise for 24 hours before sampling.(3)  
 
Immunological, virological, haemotological and biochemical results were recorded for patients 
who had been on treatment for more than 3 months. Data collected included age, weight, 
gender, race, CD4, viral load, lactate levels and clinical symptoms. It took approximately 11 
months from 2008 May to March 2009 to review the patient files which were accessed at least 3 
times in a week, with each file requiring one hour. For each patient the following data were 
recorded by the researcher:  
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Table 2.1:Nature of Data Recorded and Reasons 
Data recorded Rationale 
Demographics (age, gender, race, 
weight) 
Identify risk factors 
CD4, Viral load Severity / stage of disease 
Drug regimen and duration of treatment  Impact of these factors  
Other diseases Co-existing/contributing factors 
Clinical signs/symptoms 
Manifestations of lactate 
elevation 
 
Information was recorded and analyzed from the initiation of patient on ARTs until the date of 
collection of the data. A total of 232 patients were included in the retrospective study. 
 
The anti-retroviral guidelines produced by the Department of Health and in use by the clinic at 
that time stated that Hlac and LA should not be tested randomly but rather only on suspicion 
e.g. if the patient lost weight abruptly, had gastrointestinal symptoms or unexplained abdominal 
discomfort. However, due to the frequency of patients presenting with Hlac, Tshwane District 
Hospital changed the protocol from testing on suspicion to also testing asymptomatic patients.  
While the above strategy would provide some information in the areas detailed in Table 2.1, the 
non-systematic nature of the data collection that evolved during the review made it unlikely that 
completely accurate incidence rates would be measured. 
 
2.2.1.2Prospective Review 
In the prospective study, which was conducted between September 2008 and December 2009, 
HIV patients who had been on treatment for longer than 12 months were selected. The study 
was also performed at the Tshwane District Hospital. Convenience sampling took place from 
the queue at the clinic and patients were eligible, for lactate testing provided that they had not 
exercised or exerted themselves strenuously that morning. The inclusion criteria were as 
follows: 
1. Patients’≥18 years of age attending the clinic at Tshwane District Hospital 
2. Treatment with anti-retrovirals for ≥ 12 months 
 
Given the accuracy and cost effectiveness of a point-of-care device (see page 13, Chapter 1), 
this was the method used to measure lactate levels in this study.(27)  The device provides lactate 
results within 60 seconds of placing a drop of whole blood on the test strip, and is powered by 
three 1.5-volt batteries. The measuring range for whole blood is 0.8-22mmol/L and for plasma is 
0.7-27mmol/L.  Use of the device eliminates the need for centrifugation and specialized 
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laboratory equipment, requires a very small quantity of blood, and eliminates the need to 
transport blood specimens on ice.   
 
The collection protocol performed by a trained nurse included the following:  
 The patient was at rest for longer than 15 minutes and had not performed any exercise.  
 Venipuncture was undertaken without a tourniquet.(29) 
 
Immunological, virological, haemotological and biochemical results were recorded by the 
researcher for patients who had been on treatment for more than 12 months. Data collected 
included age, weight, gender, race, CD4, viral load, lactate levels and clinical symptoms as 
recorded in the patient files on the day of testing. Each patient took approximately 20 minutes to 
assess provided all their information was available. If a patient’s file was inaccessible, that 
patient was excluded from the study. A total of 292 patients were sampled in the prospective 
study. Using the same lactate classification as for the retrospective study, lactate levels were 
recorded and patients categorised as asymptomatic, symptomatic or LA. 
 
The data capturing for both the retrospective study and the prospective study was performed by 
the researcher. Verification of the data collected was ensured by randomly reviewing files twice 
to ensure the correct information was collated. 
 
2.3.1Ethics Clearance 
Record review in the retrospective study did not require patient consent since all data were 
anonymous. In the prospective study, patients signed consent before data and blood collection 
were performed. 
 
The study was approved by the Human Research Ethics Committee (medical). Clearance 
certificate number M071133. 
 
2.3.2Statistics 
Analysis included simple descriptive statistics and comparison of means by t-testing. Frequency 
analysis was by Chi-square or Fisher exact test. Where appropriate, simple correlations were 
sought. Regression analysis was utilised to explore relationships between multiple independent 
variables and lactic acid levels. All data were analysed using Statistica Version 9.1(StatSoft Inc, 
USA). Significance was routinely accepted with p-values <0.05. 
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The sample size for analysis in the retrospective study included 3741 subjects while sample 
size for the prospective study was according to the formula described by Casagrande et al.(38) 
Based on the statistics of previous studies which showed that up to 15-35% of patients treated 
with ART had elevated lactate, it was hypothesized that in this study the new ART regimens 
would reduce by approximately 50%.  At this rate the sample size required to give a p value(α) 
of 0.02 with a power (β) of 05% is 232. 
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CHAPTER 3 
3.RESULTS 
 
3.1RETROSPECTIVE STUDY 
3.1.1Descriptive Analysis 
A total of 3741 patient files were retrieved and reviewed covering the period from August 2004 
until December 2007.  As explained in Chapter 2, at some point the clinic policy changed from 
one of lactate testing only in the presence of symptoms, to the more frequent testing of patients 
receiving anti-retroviral treatment. This obviously resulted in a subset of the sample being in the 
asymptomatic category. Composite results showed that 232 (6.2%) patients presented with 
elevated lactate values, which may well be an under-representation for reasons described 
above.  Within this group of 232 patients, 161 were symptomatic, representing 4.3% of the total 
sample. Characteristics of the group with elevated lactate levels are summarized in Table 3.1. 
 
Table 3.1:Details of Patients in Retrospective Group with Elevated Lactate Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on known adverse effects and relative toxicity, regimens were categorized in 
increasing order as: 1a1=3TC, d4t30mg, efavirenz 1a2=3TC,d4t40mg, efavirenz 
1b1=3TC,d4t30mg ,nevirapine  1b2=3TC,d4t40mg,nevirapine 
 All Patients Female Male 
p-value 
Male vs Female 
Total Number N=232 N=183 N=49  
Average Age (years ±s.d.) 42.6(±8.7) 42.7 (±9.0) 42.1 (±6.0) NS 
Weight at ±1 year of treatment 
(Kg±s.d.) 
67.0(±11.9) 67.1(±12.0) 66.6(±11.0) NS 
Race     
        Black 231 (99.6%) 182 (78.5%) 49(21.2%)  
        Coloured 1 (0.4%) 1     (0.43%) 0   (0%)  
Regimen  
}0.058 
        1a1 90(38.8%) 70(38.3%) 20(40.8%) 
        1a2 100(43.1%) 73(39.9%) 27(55.2%) 
        1b1 18(7.8%) 17(9.3%) 1 (2.0%) 
        1b2 13(5.6%) 13(7.1%) 0 
        Varied 11(4.7%) 10(5.5%) 1(2.0%) 
CD4 (cells/µL±s.d.) 117(±80.4) 118(±76.0) 114(±93.0) NS 
Highest Lactate Value (mmol/L 
±s.d.) 
4.3(±1.8) 4.4(±2.0)  3.8(±1.0) 0.04 
Average time taken to increased 
lactate presentation (months±s.d.) 
12.0 (±5.9) 11.7 (±6.0) 13.4 (±6.0) 0.06 
Elevated Lactate Groups     
Asymptomatic (≥2.3mmol/L) 71(30.6%) 52(28.4%) 19(38.8%) 
}0.021 Symptomatic(≥2.3- 5mmol/L) 158(68.1%) 130(71.0%) 28(57.1%) 
Lactic acidosis (≥5mmol/L) 3(1.3%) 1(0.6%) 2(4.1%) 
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Overall 6.2% of the population sampled had elevated lactate levels.  Females tended to present 
earlier and had higher peak values. No absolute differences in weight were observed between 
males and females.  However, it is necessary to compare the average weights of males and 
females in this study to average weights of similarly aged subjects in the general population.  
According to the African Project on Genes in Hypertension as carried out by the Cardiovascular 
Patho-physiology and Genomics Research Unit, University of the Witwatersrand, average 
weight for females is 81.6kg and for males is 73kg.(39)  Comparing weights of the study group 
indicates that males were 91% of average weight for age versus females who were even lower 
at 82% of average weight. In other words, both males and females in the study group were 
nutritionally compromised, with females being more so than males. This suggests that patients 
who present to the clinic are at an advanced stage of the disease. CD4 counts were extremely 
low for both male and females. Regimens were similar for males and females, with a tendency 
towards more females receiving regimen 1a2.  Analysis of the three categories of lactate 
elevation indicated that the majority of patients (68.1%) were in the symptomatic group and 
there were more symptomatic females. This is the result expected from the sampling strategy at 
the hospital at the time and is almost certainly an under-representation of asymptomatic 
patients.  
 
3.1.2Symptoms versus Highest Lactate Value  
 
Table 3.2:Correlations between Symptoms and Highest Lactate Value 
Symptom 
Correlation 
Coefficient 
p-Value 
<0.05 
Peripheral neuropathy 0.209 √ 
GIT symptoms (nausea and 
vomiting) 
0.148 √ 
Abdominal tenderness 0.214 √ 
 
Peripheral neuropathy, gastrointestinal symptoms and abdominal tenderness were the only 
symptoms that were shown to be associated with high lactate values. Fatigue, diarrhoea, rash, 
upper respiratory tract infection, lipodystrophy, heartburn, breast tenderness and conjunctivitis 
did not show any significant relationship with higher lactate values. While not a symptom but 
rather a sign of disease severity, the CD4 count was found to be negatively correlated with 
lactate values (-0.258; p<0.05), indicating that lower CD4 counts were related to higher lactate 
values. 
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3.1.3Symptoms versus Regimen  
 
Table 3.3:Correlation between Symptoms and Relative Toxicities of Drug Regimens 
Symptom 
Correlation 
Coefficient 
p-Value <0.05 
Rash 0.209 √ 
Upper Respiratory Tract Infection 
(URTI) 
0.159 √ 
 
As per the sub-text below Table 3.1, regimens were categorized according to well-recognized 
adverse effects and toxicity. On this basis, rash and URTI were more frequent in subjects 
exposed to the more toxic regimens. Fatigue, peripheral oedema, nausea, vomiting, abdominal 
tenderness, diarrhoea, lipodystrophy, heartburn, breast tenderness and conjunctivitis did not 
show any significant relationship to regimen.  
 
3.1.4Multivariate Analysis 
 
Table 3.4:Factors Related to Peak Lactate 
Determinant t value p-Value  
Average time taken to increased lactate presentation 
(months) 
-2.88 0.005 
CD4( cells/µL) -2.33 0.022 
 
 
 
Figure 3.1: Relationship of Average Time (months) Taken to Increased Lactate 
Presentation from Initiation on ART with Elevated Lactate Levels 
 
Multivariate analysis taking into account gender, age, average time to increased lactate 
presentation, weight at ±1 year  of treatment and weight loss revealed that only shorter time to 
elevated lactate and lower CD4 count were predictive of peak lactate levels. These two factors 
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accounted for 10.8% of the variance in elevated lactate. Table 3.4 and Figure 3.1.shows the 
weak but significant inverse relationships. 
In summary, 6.2% of the group studied had elevated lactate levels. Some 4.3% were 
categorized as having symptomatic Hlac or LA and 0.1% as LA. The group of subjects was 
significantly below average weight for age and CD4 counts were below 200 for both males and 
females. There was an inverse correlation between CD4 count and peak lactate level. Lactate 
values correlated with symptoms of peripheral neuropathy and gastrointestinal signs and 
symptoms, whereas drug toxicity correlated with symptoms of rash and presentation with upper 
respiratory tract infection. Multivariate analysis showed only that elevated lactate was related to 
low CD4 count, and that an early rise in lactate was associated with a peak that was higher. The 
latter findings suggest that it is essentially the severity of the underlying HIV infection that is a 
determinant of lactate elevation. 
 
3.2PROSPECTIVE STUDY 
3.2.1Descriptive Statistics 
 
Table 3.5:Details of Patients in Prospective Group  
 All Patients Female Male 
p-value 
Male vs 
Female 
Total Number N=292 N=212 N=80  
Age(years±s.d.) 38.1(±9.4) 37.7(±9.6) 39.3(±8.7) NS 
Weight(Kg±s.d) 66.5(±14.5) 65.6(±14.8) 68.8(±13.5) NS 
Weight Loss(Kg±s.d) 6.3(±4.2) 6.6(±4.2) 5.5(±4.3) NS 
     Race     
             Black       (%) 286 (98%) 208(73%) 78 (27%)  
             Coloured (%) 6     (2%) 4     (67%) 2   (33%)  
Regimen     
}NS  
 
             1 (%) 181 (61.9%) 127(59.9%) 54(67.5%) 
             2 (%) 95   (32.5%) 72(34.0%) 23(28.8%) 
             3 (%) 4     (1.4%) 3(1.4%) 2(2.5%) 
             4 (%) 12   (4.2%) 9(4.3%) 1(1.2%) 
CD4( cells/µL±s.d) 295(±175.8) 315(±182.8) 241.9(±143.8) 0.015 
Total number with elevated 
lactate(mmol/L±s.d) 
71(24.3%) 54(25.5%) 17(21.3%) NS 
Elevated Lactate Groups    
}NS 
Asymptomatic(≥2.3mmol/L) 43(60%) 33(61%) 10(59%) 
Symptomatic(≥2.3mmol/L-
5mmol/L) 
26(37%) 20(37%) 6(35%) 
Lactic acidosis(≥5mmol/L) 2(3%) 1(2%) 1(6%) 
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Based on known adverse effects and relative toxicity, regimens were categorized in 
increasing order as: 1= 3tc,d4t30mg, efavirenz /nevirapine 2=azt,3tc,/ efavirenz /nevirapine 
3=abacavir,3tc,efavirenz /nevirapine 4=tenofovir,3tc,efavirenz/nevirapine 
Overall 24.3% had elevated lactate levels on routine testing, with 60% in the asymptomatic 
group and 40% being symptomatic or with LA. The CD4 counts were significantly lower for 
males in this sample.  The majority of the subjects (62%) were being treated with regimen 1 and 
there were no differences in treatment regimens between males and females.  As with the 
retrospective study, mean weight for both males and females was significantly below that of 
age-matched subjects in the general population.(39) 
 
3.2.2Symptoms versus Lactate  
Table 3.6:Correlation between Symptoms and Lactate Measurements 
Symptom 
Correlation 
Coefficient 
p-value 
p<0.05 
Diarrhoea 0.12 √ 
Nausea 0.13 √ 
 
Diarrhoea and nausea were the only symptoms that were shown to be associated with high 
lactate values. Fatigue, peripheral neuropathy, vomiting, abdominal tenderness, rash, upper 
respiratory tract infection, lipodystrophy, heartburn, conjunctivitis, breast tenderness and 
pancreatitis did not show any significant relationship with higher lactate values.  
 
3.2.3Symptoms versus Regimen  
Table 3.7:Correlation between Symptoms and Relative Toxicities of Drug Regimens 
Symptom  
Correlation 
Coefficient 
p-value 
<0.05 
Diarrhoea 0.101 √ 
Abdominal 
tenderness 
0.054 √ 
 
As per subtext below Table 3.5, regimens were categorized according to known adverse effects 
and toxicity. Based on this, diarhoea and abdominal tenderness were increasing as toxicity 
increased. Fatigue, peripheral neuropathy, vomiting, abdominal tenderness, rash, upper 
respiratory tract infection, lipodystrophy, heartburn, conjunctivitis, breast tenderness and 
pancreatitis did not show any significant relationship with treatment regimen. 
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3.2.4Multivariate Analysis  
Table 3.8:Factors Related to Lactate Values 
Determinant t value p-value 
Weight  -2.47 0.01 
CD4 cells/µL -2.29 0.02 
Weight Loss 3.47 0.005 
 
Multivariate analysis taking into account race, gender, age and regimen at high lactate level 
revealed that only low weight, low CD4 and weight loss were predictive of peak lactate levels. 
These three factors accounted for 6.2% of the variance in elevated lactate 
 
3.2.5Comparisons between Subjects with High versus Low Lactate Levels 
 
Table 3.9: Comparisons between Patients with Lactate Levels Above and Below 
2.3mmol/L 
 Elevated Lactate Normal Lactate p-value 
 Viral 
Load(copies/ml±s.d.) 
3259710.0(±395020) 81958.1(±133559) 0.014 
CD4( cells/µL±s.d) 248.9(±192.6) 305.7(±170.3) 0.031 
Weight(Kg±s.d.) 62.9(±15.2) 67.3(±14.3) 0.049 
 
This analysis showed that weight and CD4 count were lower in those with elevated lactate 
levels and viral loads were higher.  
 
In summary, 24.3% of the group studied had elevated lactate levels and 9.6% of those had 
symptomatic Hlac or LA.   As with the retrospective group, the subjects were significantly below 
average weight for age.  The mean CD4 count averaged around 300 cells/µl but was lower for 
males than for females. Female patients predominated but lactate levels were elevated in 
proportion to the genders enrolled.  
 
Lactate levels correlated with gastrointestinal symptoms, as did toxicity of the drug regimens. 
Multivariate analysis showed that lower weight, weight loss and CD4 count correlated with 
higher lactate levels, again suggesting that severity of the underlying HIV infection is a 
determinant of lactate elevation. This is consistent with the finding of significantly higher viral 
loads in the group with elevated lactate levels. 
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3.2.6Review of Retrospective and Prospective Studies 
Table 3.10:Comparisons of Subjects in Retrospective and Prospective Studies 
 Retrospective Prospective P-value 
Total number 232 292  
Female 183(78.9%) 212(72.6%) 
}NS 
Male 49(21.1%) 80(27.4%) 
Age 42.6±8.7 38.1±9.4 P<0.001 
CD4(cells/µL) 117(±80.4) 295(±175.8) P<0.001 
Weight(kg) 67.0(±11.9) 66.5(±14.5) NS 
Incidence 232(6.2%) 71(24.32%) P<0.001 
Asymptomatic 71(30.6%) 43(60.6%) 
}P<0.001 Symptomatic 158(68.1%) 26(36.6%) 
Lactate>5mmol/L 3(1.3%) 2(2.8%) 
Regimens(*)    
A 90 181  
B 100 
Not 
applicable 
 
C 18 
Not 
applicable 
 
D 13 
Not 
applicable 
 
E Not applicable 95  
F Not applicable 4  
G Not applicable 12  
Symptoms 
Significantly  
represented 
Significantly 
represented 
 
Peripheral neuropathy √ -  
GIT symptoms √ √  
Abdominal tenderness √ -  
Rash √ -  
Upper respiratory tract 
infection 
√ -  
Determinants of High 
lactate 
 
 
 
 
Average time to increased 
lactate presentation 
(months) 
√ Not measured  
Low CD4 √ √  
Weight loss Not measured √  
Low weight on entry 
Not specifically 
measured 
√  
 
*A = d4t30mg,3TC, efavirenz B = d4t40mg,3TC,  efavirenz 
C = 3TC, d4t30mg, nevirapineD = 3TC,d4t40mg, nevirapine 
             E = AZT, 3TC, Nevirapine/ efavirenz F = abacavir,3TC, efavirenz /nevirapine  
           G = Tenofovir, 3TC, efavirenz /Nevirapine 
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Male:Female ratios were similar in both the retrospective and prospective groups. The age 
groups are significantly different when comparing the two studies: subjects presented when they 
were older in the retrospective study at ±43 years compared to the prospective study were the 
average age was around 38 years. The CD4 counts were significantly higher in the prospective 
study, while the average weights in both the retrospective and prospective studies were similar 
but low when compared to the population average weight for age.  
 
Incidence rates of all the categories of Hlac (2.3mmol/L- 5mmol/L) were higher in prospective 
study, but as previously discussed, for the retrospective study the sampling strategy was 
expected to deliver a falsely low rate of Hlac. 
 
As per study design, the regimens differed between the two study groups, with the less toxic 
more recent regimens being found in the prospective group. Gastrointestinal symptoms were a 
common presentation in both the retrospective and the prospective groups even with the newer 
and supposedly less-toxic regimens. However, peripheral neuropathy, a relatively common 
problem with older regimens was not observed. 
 
Although several other factors contributed to elevated lactate levels, low CD4 count was the 
common determinant of elevated lactate levels in both the retrospective and prospective 
groups, as were other manifestations of advanced disease. 
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CHAPTER 4 
 
4.DISCUSSION  
Anti-retrovirals have revolutionized the treatment of HIV/AIDS, providing better quality of life.  
However, the use of these drugs is associated with adverse effects which reduces adherence 
and decreases patient morale. Asymptomatic and symptomatic Hlac and LA are part of the 
spectrum of mitochondrial toxicity associated with NRTI therapy.(15)  Mitochondria are small 
intracellular organelles that are located in the cellular cytoplasm. All cells except erythrocytes 
contain hundreds to thousands of mitochondria. Mitochondria have a double lipid membrane 
that is folded into numerous cristae surrounding the matrix space. This matrix contains copies of 
the mtDNA genome, which encodes subunits of four of the five complexes of the oxidative 
phosphorylation (OXPHOS) system located in the inner membrane of the mitochondrion. This 
OXPHOS system is responsible for providing most of the energy to cells.(42)  The active 
intracellular anabolites of NRTIs block viral replication by competing with cellular nucleotides for 
incorporation into proviral DNA and are relatively specific for HIV reverse transcriptase. The 
ability of NRTIs to inhibit human mtDNA is associated with toxic manifestations that include 
peripheral neuropathy, hepatic steatosis, lipoatrophy, and LA syndrome.(12)  
 
4.1RETROSPECTIVE STUDY 
The retrospective group showed an incidence of Hlac of 6.2% in the total population of 3741 
patient files reviewed. Seventy-one subjects (30.6%) were asymptomatic, 158 (68.1%) were 
symptomatic and 1.3% had LA. However, this is not a true reflection of the patients with 
elevated lactate due to the particular process of testing in the retrospective study.  The lack of 
knowledge of the health workers in respect of the condition, the clinic’s protocol, testing and 
ART guidelines which stipulated that patients should only be tested upon presentation of certain 
symptoms which led to an under-representation of the true incidence of Hlac.(42) On the other 
hand, the increase in frequency and mortality of patients presenting with Hlac and LA prompted 
the Tshwane district clinic healthworkers in 2005/2006 to test more regularly for elevated lactate 
levels, particularly, if patient fell into what was at the time considered to be the high risk profile 
i.e. female gender, obesity, prolonged ART, excellent adherence, chronic renal failure and 
pregnancy.(42)   
 
Amongst the 3741 patient files reviewed, 67% were female, but while female gender did not 
emerge as a determinant of Hlac in this study, women also had significantly higher lactate levels 
compared to the males (4.4 vs 3.8mmol/L; p 0.04).  This is in line with other studies. (12, 14, 25)  
Females also tended to present with elevated lactate levels at an earlier stage (11.7 months vs 
25 
 
13.4 months; p 0.06). Overall, this is in line with previous studies that have shown that on 
average, patients present with Hlac after 6-18 months of HAART.(12, 14, 16, 20)  Seventy-two 
percent of females fell into the symptomatic Hlac or LA group which was significantly higher 
than among males (p 0.021). This further illustrates that Hlac and LA affect females to a greater 
extent.  Although there were no significant weight differences between the females and males, it 
must be noted that the weights were below those of age-matched subjects in a comparable 
population, suggestive that subjects in this study are at an advanced stage of disease and/or 
suffering from co-morbidity such as tuberculosis. It has been shown that many factors, either 
individually or in combination, could contribute to females having different responses in terms of 
Hlac. These include better adherence, more women attending HIV clinics or hormonal 
factors.(11) Based on the above it is reasonable to propose that  healthcare workers should 
regard women as being at greater risk for manifestations of Hlac and LA and should be 
prepared to test early for the condition.   
 
Regimens tended to differ between the males and females (p 0.058) and females (37.1%) were 
on regimens with stavudine compared to males (11.6%) with 1a2 (stavudine 40mg, 3TC and 
efavirenz) combination being the most prescribed. Stavudine has been reported in several 
studies as showing strong associations with Hlac.(12, 13, 14, 16, 21, 39) 
 
Peripheral neuropathy, gastrointestinal symptoms (nausea, vomiting) and abdominal 
tenderness were the most significant symptoms associated with elevated lactate in this study. 
These symptoms have been described in several studies, and if present should indicate the 
need to test the patient for elevated lactate levels.(11,12,15,20,28,35)  
 
In this study, multivariate analysis showed that elevated lactate was related to lower CD4 count, 
and that an earlier rise in lactate was associated with a higher peak lactate value. Perez and the 
International Lactic Acidosis Group have shown that patients with advanced progression of the 
disease (low CD4) are at much higher risk of developing serious NRTI-induced mitochondrial 
dysfunction.(12,13)   
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4.2 PROSPECTIVE STUDY 
Amongst the 292 patients sampled, larger proportions were female (72.6%). The prospective 
study was done in late 2008, and the trend of more women getting tested and evaluated still 
existed.  
 
In the prospective group, as expected and as per the objective of the study, the regimens varied 
significantly from the retrospective study. This change was partly due to recognition by the 
Tshwane District Hospitals’ healthcare workers of the increasing morbidity of patients with Hlac, 
but also due to the changing national policy guidelines.  Sixty-two percent of patients were on 
stavudine 30mg, 3TC or efavirenz/nevirapine and 32.5% were on zidovudine, 3TC and 
efavirenz/ nevirapine. The removal of stavudine 40mg, the switch to stavudine 30mg and the 
introduction of patients onto zidovudine showed fewer side effects. In 2011, Matthews et al, 
showed that switching from stavudine to zidovudine in patients at risk for Hlac was beneficial in 
terms of Hlac and LA.(45) 
 
In the prospective study, the symptoms that correlated best with elevated lactate levels were 
gastrointestinal i.e. nausea and diarrhea. These symptoms were slightly less severe when 
compared to the symptoms that presented in the retrospective study significantly, and 
peripheral neuropathy was not observed. The decrease in level of severity of symptoms is likely 
related to the reduced toxicity of more-recent drug regimens.   
 
 
Low weight, low CD4 counts and weight loss were significantly predictive of elevated lactate 
levels.  When comparing viral loads, CD4 and weight between patients with elevated lactate 
and patients with normal lactate, viral loads were higher, CD4 counts lower, and weight was 
lower in patients with elevated lactate. Once again, the prospective study suggested that 
patients resort to treatment at an advanced stage of disease, also indicative that if patients’ 
immunity is compromised they are more likely to present with elevated lactate levels. Therefore, 
in keeping with recent international trends, it is prudent to initiate on ARTs at higher CD4 counts 
than previously recommended. 
 
4.3COMPARISON OF THE RETROSPECTIVE AND PROSPECTIVE STUDIES 
Seventy-nine percent and 73% were female in the retrospective and prospective study 
respectively but it should be kept in mind that females predominated in both the retrospective 
and prospective studies. 
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The average ages of the retrospective and prospective groups were 42.6(±8.7) and 38.1(±9.4) 
years (p<0.001).  This difference could be due to the change in mindset of the population at 
risk, and a reflection of the progress made in South Africa in creating awareness and in 
addressing the HIV epidemic.   
 
CD4 counts were significantly higher in the prospective group (295±175.8 vs 117±80.4; 
p<0.001). As mentioned before, this is likely the result of patients presenting earlier to be tested 
and evaluated compared to the retrospective group. Although the CD4 is higher in the 
prospective group, the value is still at the lower end of normal and as per current guidelines 
patients should be started on ART at an earlier stage in the disease. So, despite evidence that 
patients present for treatment at an earlier age, and treatment is initiated with higher CD4 
counts, South African patients still appear to be presenting with advanced disease and possibly 
also with co-morbidity. 
 
In this study, the rate of LA, when converted to a rate per 1000 patient year is 6.8 cases. This is 
significantly below the 13-20 per 1000 cited in Table 1.3 which summarises a number of 
studies.  However, in terms of the hypothesis that newer regimens would lower the incidence of 
elevated lactate levels by 50%, the observed incidence of 24.3% is no different from previously 
reported rates. This therefore shows that although regimen changes have been implemented, 
the overall incidence of Hlac is still elevated but the LA rate is significantly lower than before. 
Removal of stavudine completely from the South African ART 2010 guidelines and the use of 
tenofovir as the only first line regimen would possibly increase patient quality of life and 
decrease the incidence of symptomatic Hlac and LA. 
 
4.4CONCLUSION 
In this study, the key findings were that the overall incidence of Hlac appears to be unchanged 
with newer drug regimens, but LA occurs less frequently. Gastro-intestinal symptoms and signs 
are still observed but peripheral neuropathy does not appear to be a problem. Advanced 
disease as manifested by low weight, weight loss and low CD4 counts appear to place patients 
at a particular risk for the development of Hlac. Healthworkers need to be aware of these risk 
factors in order to monitor possible progression to Hlac and LA, and should recognize that 
Hlac/LA are likely to affect females to a greater extent than males. 
 
4.5LIMITATIONS  
In the retrospective study, the pattern of testing for Hlac was erratic and no proper clinic 
protocol was used and therefore Hlac was almost certainly underrepresented. Although, point-
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of-care measurement devices have been validated, the lower LA rates found in this study might 
be spurious. 
4.6 RECOMMENDATIONS 
Although regimen changes have been implemented, the more toxic regimens (stavudine, 
didanosine) should be removed from the South African treatment guidelines. Patients who have 
a low weight upon entry into the ART program should be closely monitored for Hlac. Patients 
who have sudden weight loss and unexplained GIT symptoms should be tested for Hlac. 
Handheld lactate meters should be formally assessed against conventional laboratory methods 
and if validated as in other studies should become a norm in every resource limited clinic to 
monitor for the development of Hlac and LA.(27) 
 
 
 
 
 
 
 
 
  
29 
 
REFERENCES 
 
1. Statistics South Africa home page, http://www.statssa.gov.za/  Last visited 2011/06/24 
 
2. UNAIDS. Report on the Global Aids Epidemic 2010. http://www.unaids.org/globalreport/. 
 
3. Eshun-Wilson I, Soentjens P, Zeier M, Taljaard J. Symptomatic hyperlactataemia and lactic 
acidosis in the era of highly active antiretroviral therapy. South African Med Journal. 2005; 
95(12):929-30. 
 
4. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard B. Hyperlactataemia and lactic 
acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. 
AIDS, 2002:16(10):1341-1349. 
 
5. Medina DJ, Tsai CH, Hsiung GD and Cheng YC. Comparison of mitochondrial morphology, 
mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human 
immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother, 1994:38:1824-
1828.  
 
6. Wohl D; Pilcher C Christopher D,Evans S, Manuel R, McComsey G, G Yang, R Zackin, R Alston, B 
Welch, S Basar, M Kashuba, A Kondo, P Martinez, A Koletar, Absence of sustained 
hyperlacatatemia in HIV- infected patients with risk factors for mitochondrial toxicity. Journal 
of Acquired Immune Deficiency Syndromes, 2004:35(3):274-278.  
 
7. Department of Health. http://www.doh.gov.za/. Last visited 2011/05/23. 
 
8. The American Academy of Family Physicians. http://www.aafp.org/. Last visited 2011/03/04. 
 
9. South African HIV Clinicians Society. Antiretroviral Therapy in Adults. South African Journal of 
HIV Medicine, 2008:18-31. 
 
10. HIVINSITE. http://hivinsite.ucsf.edu/. Last visited 2011/04/02 
 
11. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD. 
Low efficacy and high frequency of adverse events in a randomized trial of the triple 
nucleoside regimen abacavir, stavudine and didanosine. AIDS, 2003:17(14):2045-2052. 
 
12. Hernández Pérez E, Dawood H. Stavudine-Induced Hyperlactatemia/Lactic acidosis at a 
Tertiary Communicable Diseases clinic in South Africa. Journal of the International Association 
of Physicians in AIDS Care, 2010:9(2):109-112. 
 
13. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe 
hyperlacatataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS, 
2007:21(18):2455-2464. 
 
14. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic 
hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, south 
Africa. Clinical Infectious Diseases, 2007:45(2):254-260. 
 
15. Fabian J, Venter WD, Mkhabela L, Levin JB, Baker L, Naicker S. Symptomatic hyperlactataemia 
in adults on antiretroviral therapy: A single-centre experience. South African Medical Journal, 
2008:98(10):795-800. 
30 
 
16. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside 
reverse transcriptase inhibitor(NRTI)- induced lactic acidosis in HIV-infected patients in a 
South African context. South African Medical Journal, 2006:96:722-724. 
 
17. http://www.immunopaedia.org.za/typo 3 temp/pics/5f52aaf63c.jpg.  Last visited 2011/05/21. 
 
18. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV- infected patients 
receiving antiretroviral therapy. Clinical Nutrition, 2005:24(1):5-15.  
 
19. Manosuthi W, Prasithsirikul W, Chumpathat N, Suntisuklappon B, Athichathanabadi C, 
Chimsuntorn S, Sungkanuparph S.. Risk factors for mortality in symptomatic hyperlactatemia 
among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. 
International Journal of Infectious Diseases, 2008:12(6):582-586. 
 
20. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. Risk factors for and clinical characteristics of 
severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. 
HIV Medicine, 2010:11:121-129 
 
21. Marceau G, Sapin V, Jacomet C, Ughetto S, Cormerais L, Regagnon C, Dastugue B, Peigue-
Lafeuille H, Beytout J, Laurichesse H. Frequency, risk factors, and outcome of 
hyperlactataemia in HIV-positive persons: Implications for the management of treated 
patients. Clinical Chemistry, 2003:49:1154-1162. 
 
22. Southern African HIV Clinicians Society. http://www.sahivsoc.org/ Guidelines for prevention, 
diagnosis and management of NRTI-associated symptomatic hyperlactataemia and lactic 
acidosis. 
 
23. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi 
E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A. Hyperlactatemia and Antiretroviral 
therapy: The Swiss HIV Cohort study. Clinical Infectious Diseases, 2001:33: 1937-1937. 
 
24. Brinkman K, ter Hofstede HJ. Mitochondrial toxicity of nucleoside analogue reverse 
transcriptase inhibitors: lactic acidosis,risk factors and therapeutic options. AIDS Reviews, 
1999:1:141-148. 
 
25. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van 
Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, 
Marlink RG. Higher-than-expected rates of lactic acidosis among highly active antiretroviral 
therapy-treated women in Botswana: Preliminary results from a large randomized clinical 
trial. Journal of Acquired Immune Deficiency syndrome, 2007:46(3):318-322. 
 
26. Daher EF, Cezar LC, Silva GB Jr, Lima RS, Damasceno LS, Lopes EB, Nunes FR, Mota RS, 
Libório AB. Metabolic Acidosis in AIDS patients. Archives of Medical Research, 2009:40(2): 109-
113. 
 
27. Ivers LC, Mukherjee JS, Joia S. Point of care testing for antiretroviral therapy-related lactic 
acidosis in resource-poor settings. AIDS, 2006:20(5):779-780. 
 
28. Moore JM, James CB, Nolan IR, Upton D, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in 
HIV-1-infected patients taking antiretroviral therapy. AIDS, 2001:15:717-723.  
 
29. Perez EH, Dawood H, Chetty U, Esterhuizen TM , Bizaare M. Validation of the Accutrend lactate 
meter for hyperlacatatemia screening during antiretroviral therapy in a resource-poor 
setting. International Journal of Infectious Diseases, 2008:12(3):553-56. 
31 
 
30. Boulassel MR, Morales R, Murphy T,Lalonde RG, Klein MB. Gender and Long-Term Metabolic 
toxicities from antiretroviral therapy in HIV-1 infected persons. Journal of Medical Virology, 
2006:79:1158-1163. 
 
31. Currier JS. Sex differences in antiretroviral therapy toxicity: Lactic acidosis, stavudine and 
women. Clinical Infectious Diseases, 2007:45(2):261-265. 
 
32. McComsey GA, Lo Re V, O’Ridordan M, Walker UA, Lebrecht D, Baron E. Mounzer K, Frank I. 
Effect of reducing the dose of stavudine on body composition, bone density and markers of 
mitochondrial toxicity in HIV-infected subjects a randomized, controlled study. Clinical 
Infectious Diseases, 2008:46(8):1290-1300. 
 
33. Hill A, Ruxrungtham K, Havanich M et al. Meta-analysis of efficacy and safety for clinical 
studies of d4T 40mg versus 30mg BID in 1008 patients. Abstract no. THPE0120.XVI 
International AIDS Conference, Vancouver, 2006. 
 
34. Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative 
nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS, 
2003:17(17):2495-2499. 
 
35. Lonergan JT, McComsey GA, Fisher RL, Shalit P, Thomas M, Ward DJ, Williams VC, Hessenthaler 
SM, Lindsey L, Hernandez JE. Lack of recurrence of hyperlactatemia in HIV-infected patients 
switched from stavudine to Abacavir or Zidovudine. Journal of Acquired Immune Deficiency 
Syndromes and Human Retrovirology, 2004:36(4):935-942. 
 
36. Sundaram M, Srinivas CN, Shankar EM, Deepak M, Murugavel KG, Balakrishnan P, Solomon S, 
Kumarasamy N. Co-factors for abnormal lactate levels among persons with HIV disease at a 
tertiary HIV care setting in South India. Food and Chemical Toxicology. 2008:46(8):2823-2825. 
 
37. International AIDS society-USA. https://www.iasusa.org/pub/topics/2003/issue2/55.pdf. Last 
visited April 2011. 
 
38. Casagrande JT, Pike MC, Smith PG. An improved approximate formula for calculating sample 
sizes. Biometrics, 1978:34:483-486. 
 
39. Hocqueloux L, Alberti C, Feugeas J-P, Lafaurie M, Lukasiewicz, Bagnard G, Carel O, Erlich D, 
Molina J-M. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected 
patients. HIV Medicine, 2003:4:18-23. 
 
40.  Arenas-Pinto A, Grant AD, Edwards S, Weller IVD. Lactic acidosis in HIV infected patients: a 
systematic review of published cases. Sexually Transmitted Infections, 2003:79:340-343. 
 
41. Datta D, Moyle G, Mandalia S, Gazzard B. Matched case-controlled study to evaluate risk 
factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV Medicine, 2003: 
4(4):311-314. 
 
42. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on 
antiretroviral treatment: a continuum or distinct underlying mechanisms. Journal of 
Antimicrobial Chemotherapy, 2009:64(5):901-909. 
 
43. National Department of Health. National antiretroviral treatment guidelines. 2004:66. 
 
44. Department of Social Development. http://www.population.gov.za/pop_dev/index.php/. Last 
visited 2011/06/23. 
32 
 
 
45. Matthews LT, Giddy J, Ghebremichael M, Hampton J, Guarino AJ, Ewusi BA , Carver E, Axten K, 
Geary MC, Gandhi RT, Bangsberg DR. A Risk-Factor Guided Approach to Reducing 
Lactic Acidosis and Hyperlactatemia in Patients on Antiretroviral Therapy. PLoS ONE 
6(4): e18736. doi:10.1371/journal.pone.0018736 
 
46. South African National AIDS Council (2010) The South African Antiretroviral Treatment Guidelines. 
Department of Health; p 8. 
  
33 
 
APPENDIX A 
 
 Retrospective Study  
34 
 
RETROSPECTIVE STUDY 
          
 
          
 
Race* 1 - White 2 - Indian 3 - Coloured 4 - Black            
Gender** 1 - Female First lactate v 2 - Male              
Asympt (2.3-5)= 1 Sympt=(2.3-5)=2 LA=>5 =3       
  
 
          
 
          
 
Number Patient  Race Gender Age Weight CD4 Viral Length of Time  Lactate Time on  
 
Number A-Asian M-male in years kg 
 
Load on Treatment Level ( mmol/L) Txt when  
  
B-Black F-female 
    
Months 
 
Lactate Occurred 
  
 
C-Coloured 
   
  
   
Months 
    W-White 
 
        
 
   
    
 
               
    
 
               
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
1A-STAVUDINE+LAMIVUDINE+EFAVIRENZ  
1B-STAVUDINE+LAMIVUDINE+NEVIRAPINE  
2- KALETRA+ZIDOVUDINE+DIDANOSINE  
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Retrospective Study Table cont. page 2  
        
 
Initial regimen Was the Stavudine New  Weight Loss GIT symptoms Cholesterol Peripheral Hepatitis TB 
1A Dose Changed Regimen (kg) Diarrhea, Vomiting, Levels Neuropathy Type Type 
1B  or 2  from 30mg to 40mg 
 
  Nausea, Stomach Cramps mmol/L Y-Yes A,B or C Y- Yes 
 
          N-No 
 
N-No 
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Retrospective Study Table cont. page 3 
       lipodystropy Insulin  Other  Chronic  Other  Other  Other  
Y-Yes  Levels diseases conditions diseases Drugs Symptoms 
N-No mmol/L   e.g. diabetes e.g. malignancies e.g. Fluconazole   
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PROSPECTIVE STUDY 
 
          
  
   
Gender 
 
Race  
 
Regimen 
  
  
   
Female 1 
 
1 white 
 
1= 3tc,d4t30mg,efv/nvp 
   
Male 2 
 
2 Indian 
 
2= azt,3tc,efv/nvp 
     
3 coloured 
 
3=abc,3tc,efv/nvp 
     
4 black 
 
4=tenofovir,3tc,efv/nvp 
          
  
Number Patient  Race Gender Age Height Weight CD4 Viral Lactate  Lactate Time on  
  Number  A-ASIAN M-MALE in years cm kg count Load Before txt Level (mmol/L) Txt when  
  
B-BLACK F-FEMALE 
   
cells/mm
3
 
 
mmol/ L  lactate occurred 
    C-COLOURED 
 
      
 
  
 
   
    W-WHITE                 
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Prospective Study Table cont. page 2 
 
 
        
 
Creatine Transaminase Initial regimen Was the d4t  New Regimen Weight Loss GIT Symptoms Cholesterol Peripheral 
Clearance Levels 1A Regimen Changed   kg Diarrhea, Vomiting, Levels Neuropathy 
mL/min u/L 1B  or 2  from 30mg to 40mg     Nausea, Stomach  mmol/L Yes or No 
    or other       Cramps    
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
1A-STAVUDINE+LAMIVUDINE+EFAVIRENZ  
1B-STAVUDINE+LAMIVUDINE+NEVIRAPINE  
2- KALETRA+ZIDOVUDINE+DIDANOSINE  
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Prospective Study Table cont. page 3 
 
        
Lipodystropy Insulin  Other  Chronic  Other  Other  Other  
 Yes or No Levels Diseases Conditions Diseases Drugs Symptoms 
       e.g. Diabetes e.g. Malignancies e.g. Fluconazole   
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INFORMED CONSENT 
 
Hello, 
 
I am Veni Padayachee, a researcher in the Department of Pharmacy at Wits Medical School. I am 
interested in finding out more about the risk factors of a condition called lactic acidosis in patients on 
anti-retroviral drugs. Lactic acid is found in your body when you exercise and sometimes when you take 
certain medicines .If the lactic acid is not used up then it stays in your blood. A person who has too 
much of this can have weight loss, nausea (feel like vomiting), vomiting, tiredness and other symptoms 
that can be sometimes serious. There are scientific studies that indicate that patients on ARVs can 
have this problem 
 
I would like to study which patients are at risk for this problem so that we can better prevent this 
problem. I am inviting you to take part in this research study. Before you decide, it is important for you 
to understand why the research is being done and what it involves. Please read the following 
information carefully and discuss it with your friends or someone you trust. Please do not hesitate to 
ask the doctor or nurse or me if there is something you don’t understand or you need more information 
on. If you are unhappy about the study you don’t have to take part in the study. The decision is entirely 
yours. 
It does not affect your care at this clinic. 
 
WHY ARE WE DOING THIS STUDY? 
 
The study will look at the different aspects that could increase the amount of lactate in your body. Anti-
retrovirals have shown to increase the life span of individuals who are HIV positive. But, the same anti-
retrovirals can cause unpleasant effects, like lactic acidosis. We would like to find out more about what 
causes these unpleasant effects. We would like to know how these drugs affect you. We will check if it 
makes you tired or sick, nauseous or gives you diarrhea. The Human Research Ethics Committee has 
reviewed this study to ensure your rights are protected at all times. 
 
IF YOU TAKE PART IN THIS STUDY WHAT WILL HAPPEN? 
 
If you decide to take part in this study, we will need a small amount of blood at 3 and 5 months. We will 
prick your finger with a needle and then put the blood onto a test strip and into a machine. Your name 
and other details will not be used in this study. Your identification will be a code. This code will be able 
to identify you as the patient and can only be accessed by the researcher. This list will be kept locked in 
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an office.We will need your height and weight before and during the study. Other information will also 
be asked like if you take other medication (from the doctor or if you buy medication from the pharmacy) 
or if you take traditional medication. Once again, all this information is kept confidential and no one but 
the researcher can link this information to you. 
 
If you do not understand anything or if you need more information, please don’t hesitate to ask. You 
can, at any time decide to withdraw from the study. If you decide to take part in this study, we will ask 
you to sign a consent form indicating that you understand what the study is about. 
 
WITHDRAWAL FROM THE STUDY 
 
Your participation in the study is up to you. You can decide not to continue in the study at any time 
without any reason. If you decide to stop participating in the study it will not affect your future treatment 
in any way. 
 
COMPENSATION AND EXPECTED BENEFITS 
 
There will be no financial gain or any other direct benefits if you take part in the study. The medical 
information gained from the study will help doctors, pharmacists and nurses to be able to diagnose 
lactic acidosis easily, and to help to prevent this problem in you land other patients. 
 
CONFIDENTIALITY 
 
We will need to look at your hospital and clinic records. We need to check details of illnesses you have 
had previously and some personal information like your age, weight and height. Your medical data and 
the results of this study will be recorded. By signing the informed consent you are giving us right to 
access such information. If the results of this research are to be published your personal information 
and your identity will not be revealed. Your HIV status will not be revealed to anyone without your 
consent. 
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CONTACT NUMBERS 
Any symptoms, adverse events or injuries occurring during the course of the trial must be reported 
without delay to the study coordinator (Mrs Veni Padayachee)/ nurse or counselor 
 
The contact detail for the study coordinator is: 
Mrs Veni Padayachee 
Department of Pharmacy and Pharmacology 
Faculty of Health Sciences 
Wits Medical school 
University of Witwatersrand 
7 York Road  
Parktown,Johannesburg 
Neelaveni.padayachee@wits.ac.za 
Telephone Number: 0117172269 or 0117172552 (Secretary-leave a message) 
 
Contact details for the Supervisors: 
Ms Shirona Naidoo 
Department of Pharmacy and Pharmacology 
Faculty of Health Sciences 
Wits Medical school 
University of Witwatersrand 
7 York Road  
Parktown, Johannesburg 
Telephone Number: 0117172268 
 
Prof Alan Rothberg 
School of Therapeutic Sciences 
Wits Medical school 
University of Witwatersrand 
7 York Road  
Parktown,Johannesburg 
Telephone Number: 0117172064 
  
45 
 
If you are concerned with the conduct of the study or you feel that your rights are being abused as a 
participant you are free to contact the chair of the human research committee. 
 
Contact details for the Human Research Ethics Committee (Medical) 
Professor PE Cleaton-Jones (Chairman) 
Faculty of Health Sciences 
Wits Medical School.   
University of Witwatersrand 
7 York Road. Parktown, Johannesburg 
Telephone Number: 0117172130 
 
Ms Anisa Keshav (Administrative Officer) 
Senate House 
University Of Witwatersrand 
Jorrisen  Street, Braamfontein. Johannesburg 
Telephone Number: 011717 1234 
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PATIENT INFORMED CONSENT FORM 
 
The risk factors of lactic acidosis in HIV positive patients receiving Anti-retroviral Therapy 
 
I have fully understood the above information about this study, which I have read or which has been 
read or translated to me. I understand what will be required of me if I take part in the study. 
 
My questions concerning this study have been answered by   ………………………. 
 (Name of study staff member) 
 
I agree to take part in this study:                          Yes / No (answer to be circled) 
 
I understand that I may withdraw from the study at any time without giving a reason and without 
affecting my normal care and management. 
      Yes/No (answer to be circled) 
 
Participants signature ……………………….  Date ……………………….. 
Participants name …………………………………………………………… 
 
If the information sheet and consent form were translated or explained to the participant please enter 
the name of the translator here and their signature: 
 
Translator signature ……………………… Date ………………………….. 
Translator name …………………………………………………………….. 
 
If the participant gave verbal consent, please enter the name of the person who witnessed the consent 
here and their signature: 
 
Witness signature ………………………… Date …………………………… 
Witness name …………………………………………………………………. 
 
Name and signature of investigator or designated investigator taking consent 
 
Investigator signature ……………………… Date……………………………. 
Investigator name………………………………………………………………. 
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